Executive SummaryBristol-Myers Squibb patent is valid, the International Trade Commission concludes in a final determination March 15. The commission determined that the valid patent rendered illegal the importation of the product by generic competitors Biocraft and Purepac. Cease and desist orders were issued against the generic companies prohibiting domestic marketing of the antibiotic; a limited exclusion order prohibiting importation was issued against foreign firms GEMA, Istituto Biochimico Italiano Industria Giovanni Lorenzini and Institut Biochimique. Bond for all the companies included in both orders has been set at 68% of the entered value of the imported articles during a 60-day Presidential review period. If the final determination is not rejected, the orders hold until the patent expires in 2002, or an appeal. The cease and desist orders corroborate temporary orders in place since Jan. 10 ("The Pink Sheet" Jan. 22, "In Brief").
You may also be interested in...
ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.
Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).
CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.